Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is app...

Full description

Bibliographic Details
Main Authors:	Ernesto Rossi, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Tommaso Dosa, Maurizio Martini, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-04-01
Series:	Frontiers in Oncology
Subjects:	BRAF MEK target therapy conjunctival melanoma
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00232/full

id	doaj-0ff47a07709a4004b7e295e34d3f7e44
record_format	Article
spelling	doaj-0ff47a07709a4004b7e295e34d3f7e442020-11-25T01:07:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-04-01910.3389/fonc.2019.00232427769Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival MelanomaErnesto Rossi0Brigida Anna Maiorano1Monica Maria Pagliara2Maria Grazia Sammarco3Tommaso Dosa4Maurizio Martini5Guido Rindi6Emilio Bria7Maria Antonietta Blasi8Giampaolo Tortora9Giovanni Schinzari10Medical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyMedical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyOphtalmology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyOphtalmology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyMedical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyPathology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyPathology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyMedical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyOphtalmology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyMedical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyMedical Oncology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, ItalyConjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.https://www.frontiersin.org/article/10.3389/fonc.2019.00232/fullBRAFMEKtarget therapyconjunctivalmelanoma
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Ernesto Rossi Brigida Anna Maiorano Monica Maria Pagliara Maria Grazia Sammarco Tommaso Dosa Maurizio Martini Guido Rindi Emilio Bria Maria Antonietta Blasi Giampaolo Tortora Giovanni Schinzari
spellingShingle	Ernesto Rossi Brigida Anna Maiorano Monica Maria Pagliara Maria Grazia Sammarco Tommaso Dosa Maurizio Martini Guido Rindi Emilio Bria Maria Antonietta Blasi Giampaolo Tortora Giovanni Schinzari Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma Frontiers in Oncology BRAF MEK target therapy conjunctival melanoma
author_facet	Ernesto Rossi Brigida Anna Maiorano Monica Maria Pagliara Maria Grazia Sammarco Tommaso Dosa Maurizio Martini Guido Rindi Emilio Bria Maria Antonietta Blasi Giampaolo Tortora Giovanni Schinzari
author_sort	Ernesto Rossi
title	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
title_short	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
title_full	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
title_fullStr	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
title_full_unstemmed	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
title_sort	dabrafenib and trametinib in braf mutant metastatic conjunctival melanoma
publisher	Frontiers Media S.A.
series	Frontiers in Oncology
issn	2234-943X
publishDate	2019-04-01
description	Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
topic	BRAF MEK target therapy conjunctival melanoma
url	https://www.frontiersin.org/article/10.3389/fonc.2019.00232/full
work_keys_str_mv	AT ernestorossi dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT brigidaannamaiorano dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT monicamariapagliara dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT mariagraziasammarco dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT tommasodosa dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT mauriziomartini dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT guidorindi dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT emiliobria dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT mariaantoniettablasi dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT giampaolotortora dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma AT giovannischinzari dabrafenibandtrametinibinbrafmutantmetastaticconjunctivalmelanoma
_version_	1725187122296520704

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Similar Items